Similar articles

• Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.

  Wheler J, Johnson M, Seidman A. Wheler J, et al. Semin Oncol. 2006 Dec;33(6):672-80. doi: 10.1053/j.seminoncol.2006.08.018. Semin Oncol. 2006. PMID: 17145347 Review.
• The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.

  Poole R, Paridaens R. Poole R, et al. Curr Opin Oncol. 2007 Nov;19(6):564-72. doi: 10.1097/CCO.0b013e3282f1c523. Curr Opin Oncol. 2007. PMID: 17906453 Review.
• Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.

  Carpenter R. Carpenter R. Eur J Surg Oncol. 2008 Jul;34(7):746-55. doi: 10.1016/j.ejso.2008.01.011. Epub 2008 Mar 4. Eur J Surg Oncol. 2008. PMID: 18296017 Review.
• Tamoxifen or aromatase inhibitors in breast cancer: efficacy and safety.

  Neven P, Van Den Broecke R. Neven P, et al. Acta Chir Belg. 2007 Jun;107(3):240-56. doi: 10.1080/00015458.2007.11680051. Acta Chir Belg. 2007. PMID: 17685248 Review. No abstract available.
• Commentary: optimal adjuvant endocrine therapy of postmenopausal breast cancer.

  Cunnick G, Mokbel K. Cunnick G, et al. Int J Fertil Womens Med. 2005 Sep-Oct;50(5 Pt 1):197-8. Int J Fertil Womens Med. 2005. PMID: 16468468